New Photoimmunotherapy Approach Targets T Cells and Tumor Antigens

Key Takeaways

  • An activatable photoimmunotherapy (PIT) platform designed to remain quenched until enzymatic activation occurs within target cells (Vertamax) was associated with depletion of pathogenic cells, new research suggests.
  • In preclinical experiments, CD5-directed vertamax-PIT depleted T cells in healthy human skin biopsies and pathogenic T cells in a single cutaneous T-cell lymphoma (CTCL) biopsy.
  • EGFR-targeted vertamax-PIT inhibited tumor growth in vivo without detectable off-target toxicity.
08/11/2026

A new activatable photoimmunotherapy platform may enable more selective depletion of pathogenic cells while limiting inflammatory effects associated with existing PIT approaches, according to new research.

Photoimmunotherapy combines antibody-mediated targeting with light-activated cytotoxicity, allowing cell depletion to be controlled spatially and temporally. However, the investigators noted that the clinical-stage PIT agent cetuximab–IR700 can cause inflammation, swelling, and edema, potentially limiting applications outside oncology.

Activatable PIT Targets T Cells and Tumor Antigens

Kercher and colleagues developed vertamax, a benzoporphyrin-based antibody–photosensitizer conjugate platform engineered to remain quenched until enzymatically activated inside target cells. The investigators evaluated conjugates directed against T-cell antigens CD2 and CD5 and the tumor-associated antigen EGFR.

CD5-directed vertamax-PIT selectively depleted T cells in healthy human skin biopsies. The approach also depleted pathogenic T cells in a biopsy obtained from a single patient with cutaneous T-cell lymphoma. In an in vivo tumor model, EGFR-targeted vertamax-PIT inhibited tumor growth without detectable off-target toxicity, distinguishing its observed effects from IR700-PIT in the experiments.

The authors concluded that vertamax represents a potentially safer alternative PIT platform with possible applications in oncology, autoimmunity, and other diseases in which minimizing inflammation is important.

Source

Kercher E, et al. Journal of Investigative Dermatology. 2026. Doi:10.1016/j.jid.2026.07.025
Register

We're glad to see you're enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free